343 related articles for article (PubMed ID: 12774062)
1. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
[No Abstract] [Full Text] [Related]
2. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
4. Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD.
Milone JH; Prates V; Bordone J; Napal J; Garcia C
Bone Marrow Transplant; 2003 Aug; 32(3):343. PubMed ID: 12858210
[No Abstract] [Full Text] [Related]
5. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients.
Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R
Haematologica; 2003 May; 88(5):597-9. PubMed ID: 12745281
[No Abstract] [Full Text] [Related]
7. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
8. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
[TBL] [Abstract][Full Text] [Related]
9. [Hematopoietic stem cell transplantation for multiple myeloma].
Kanda Y
Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
[No Abstract] [Full Text] [Related]
10. Treatment of multiple myeloma: an emphasis on new developments.
Kyle RA; Vincent Rajkumar S
Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
[TBL] [Abstract][Full Text] [Related]
11. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Palareti G; Tura S; Baccarani M
Haematologica; 2004 Jul; 89(7):826-31. PubMed ID: 15257934
[TBL] [Abstract][Full Text] [Related]
12. Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB
J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
Palumbo A; Falco P; Ambrosini MT; Petrucci MT; Musto P; Caravita T; Pregno P; Bertola A; Cavallo F; Ciccone G; Boccadoro M
Eur J Haematol; 2005 Nov; 75(5):391-5. PubMed ID: 16191088
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
16. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
[No Abstract] [Full Text] [Related]
17. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.
Breitkreutz I; Lokhorst HM; Raab MS; Holt Bv; Cremer FW; Herrmann D; Glasmacher A; Schmidt-Wolf IG; Blau IW; Martin H; Salwender H; Haenel A; Sonneveld P; Goldschmidt H
Leukemia; 2007 Jun; 21(6):1294-9. PubMed ID: 17377586
[TBL] [Abstract][Full Text] [Related]
19. [New treatment strategies for multiple myeloma].
Ozaki S
Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
[No Abstract] [Full Text] [Related]
20. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
Abdelkefi A; Torjman L; Ben Romdhane N; Ladeb S; El Omri H; Ben Othman T; Elloumi M; Bellaj H; Lakhal A; Jeddi R; Aissaouï L; Saad A; Hsaïri M; Boukef K; Dellagi K; Ben Abdeladhim A
Bone Marrow Transplant; 2005 Aug; 36(3):193-8. PubMed ID: 15968290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]